GREY:IMVIF - Post by User
Post by
Biotech010on Mar 18, 2021 3:21pm
304 Views
Post# 32828202
DLBCL trial
DLBCL trial I spoke to the company yesterday. Doing a phase 2b does not preclude an accelerated approval. In the first part they want to repeat the data they had in the PDL-1 positive population in a greater number of patients. And then they would ask accelerated approval. Interim data is planned for Q1 2022.